Product: SPEAR UltraDetect BD-pTau 217

Enhance Neurodegenerative Detection and Monitoring with BD-pTau 217 and α-Syn

BD-pTau 217 and Alpha-Synuclein Biomarker Detection On-Demand Webinar Watch this on-demand webinar to learn how BD-pTau 217 and alpha-synuclein biomarker detection can support neurodegenerative disease research, including Alzheimer’s disease, Parkinson’s disease, and related synucleinopathies. Reliable measurement of blood-based neurodegenerative biomarkers remains a significant challenge, particularly for low-abundance targets such as brain-derived pTau 217, total alpha-synuclein, and pS129-alpha-synuclein. In […]

Read More

SPEAR UltraDetect™ BD-pTau 217 Assay

Plasma pTau 217 is one of the strongest blood biomarkers for Alzheimer’s disease (AD), but emerging evidence shows circulating pTau 217 is not exclusively brain-derived. Peripheral conditions and physiological confounders can impact total plasma measurements — particularly in early-stage and screening populations. The SPEAR UltraDetect™ BD-pTau 217 Assay was developed to preferentially detect CNS-derived, low–molecular-weight […]

Read More